, a = 13.8536(12) Å,
. 
Source of material
The title compound was synthesized according to a reported procedure [6] . A mixture of 3,5-cyclohexanedione (10 mmol), 4-nitrobenzaldehyde (10 mmol), malononitrile (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was re uxed for 2-3 h and then cooled to room temperature. After ltering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried under a vacuum.
Experimental details
Carbon-bound and Nitrogen-bound H atoms were placed in calculated positions and were included in the re nement in the riding model approximation, with U iso (H) set to 1.2Ueq(C).
Discussion
Pyrans are well-known natural products displaying a broad range of biological activities [1] . More recently, other activities have been described for these compounds such as antidepressant, vasorelaxant and platelet-aggregation inhibition, enzymatic inhibition of MAO, antioxidant activity, and proapoptotic activity [2, 3] . The discovery, structural modi cation and structure-activity relationships studies of pyrans as anti-cancer agents, have been the object of several updates and reviews [4, 5] .
In the crystal structure of the title compound, the 4H-pyran ring is nearly planar whereas the adjacent ring containing the keto group is folded. The 4H-pyran ring plane is almost perpendicular to the nitro-phenyl moiety.
